"As reported by the Washington Post prior to the event, Trump announced the pharmaceutical giants Eli Lilly and Novo Nordisk will lower the price of their weight-loss drugs for some patients on Medicare and Medicaid. In an Oval Office press conference, Trump called the deal a "triumph for American patients that will save lives and improve the health of millions and millions of Americans." The companies have reportedly agreed to lower the price of their notoriously expensive suite of weight-loss GLP-1 drugs, likely as a result of pressure from the Medicare and Medicaid innovation center (CMS)."
"By mid-2026, WaPo reports, Eli and Novo will start selling doses of their weight-loss drugs to Medicare for a minimum of $149 and a maximum of $245. As the paper notes, patient co-pays for weight-loss treatment are expected to hover around $50 a month on the plans. There's a catch, however: based on what we know, only around 10 percent of Medicare beneficiaries would be eligible for the new pricing plan, based on preexisting conditions and body mass index."
Donald Trump announced agreements with Eli Lilly and Novo Nordisk to reduce prices of GLP-1 weight-loss drugs for certain Medicare and Medicaid patients. The companies plan to sell doses to Medicare by mid-2026 at prices ranging from $149 to $245, with patient co-pays expected around $50 per month. Eligibility for the new pricing is limited, covering roughly 10 percent of Medicare beneficiaries based on preexisting conditions and body mass index. The Centers for Medicare & Medicaid Services had proposed experimental coverage changes to allow state plans to opt in. A government-run drug site called TrumpRx.gov is planned to launch next year.
Read at Futurism
Unable to calculate read time
Collection
[
|
...
]